Table 1.
Characteristics of the neuroendocrine tumor (NET) patients and the healthy controls.
| NET Patients |
Healthy Controls |
|
|---|---|---|
| Number of patients (n) | 56 | 49 |
| Gender | ||
| Male | 30 (54%) | 14 (29%) |
| Female | 26 (46%) | 35 (71%) |
| Age (years) | ||
| Mean/Median | 61.57/64.30 | 53.36/54.50 |
| Tumour grade | ||
| G1 | 38 (68%) | N/A |
| G2 | 18 (32%) | |
| Disease stage | ||
| I + II | 22 (39%) | N/A |
| III | 10 (18%) | |
| IV | 24 (43%) | |
| Disease stage | ||
| SD | 10 (18%) | N/A |
| PD | 24 (43%) | |
| Disease extent-metastases | ||
| yes | 34 (61%) | N/A |
| no | 22 (39%) | |
| NET site: | ||
| Gastrointestinal | 21 (38%) | |
| Pancreatic | 23 (42%) | N/A |
| Unknown | 6 (11%) | |
| Lung/Thymus | 4/1 (9%) | |
| Functionality status: | ||
| NF-NET | 45 (80%) | N/A |
| F-NET: CS/Glucagonoma | 11: 10/1 (20%) | |
| Previous surgery | ||
| yes | 29 (52%) | N/A |
| no | 27 (48%) | |
| Kind of SSAs therapy: | ||
| Sandostatin LAR 30 mg | 14 (25%) | N/A |
| Somatuline Autogel 120 mg | 42 (75%) |
Data are shown as median, mean, number, and percentage (%). Abbreviations: N/A, not applicable; NF-NET, non-functioning NET; F-NET, functioning NET; CS, carcinoid syndrome; PD, progressive disease; SD, stable disease; SSAs, somatostatin analogues.